Literature DB >> 24876477

Target small firms for antibiotic innovation.

Thomas J Hwang1, Daniel Carpenter2, Aaron S Kesselheim3.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24876477     DOI: 10.1126/science.1251419

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  4 in total

1.  Accelerating innovation in rapid diagnostics and targeted antibacterials.

Authors:  Thomas J Hwang; John H Powers; Daniel Carpenter; Aaron S Kesselheim
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908

Review 2.  Global financing and long-term technical assistance for multidrug-resistant tuberculosis: scaling up access to treatment.

Authors:  Thomas J Hwang; Salmaan Keshavjee
Journal:  PLoS Med       Date:  2014-09-30       Impact factor: 11.069

Review 3.  A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics.

Authors:  Matthew J Renwick; David M Brogan; Elias Mossialos
Journal:  J Antibiot (Tokyo)       Date:  2015-10-14       Impact factor: 2.649

Review 4.  Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012.

Authors:  Thomas J Hwang; Julie C Lauffenburger; Jessica M Franklin; Aaron S Kesselheim
Journal:  JACC Basic Transl Sci       Date:  2016-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.